PBE — Invesco Dynamic Biotechnology & Genome ETF

PCX · Health Care · Health Care · CIK ·
Last close
$97.30
Market Cap
$442.72M
52W High
$98.32
52W Low
$79.81
ADV30
40,236
Next earnings
The investment seeks to track the investment results (before fees and expenses) of the Dynamic Biotech & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.
No quarterly fundamentals indexed for this ticker.

Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $70.00 · spot: $98.61 · call volume: 90 · put volume: 1

News headlines (Yahoo Finance, 1h cache)

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
2026-08-13 10:20 · Yahoo
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
2026-08-12 10:20 · Yahoo
ETF Showdown: XBI vs PBE, Which Biotech Fund Wins?
2026-07-24 12:15 · Yahoo
Inside the Recent Strength in Biotech ETFs
2025-11-21 13:00 · Yahoo
2 ETFs to Watch for Outsized Volume on Biotechnology Stocks
2025-11-18 13:46 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.